Provided by Tiger Fintech (Singapore) Pte. Ltd.

DELCATH SYSTEMS INC

11.63
+0.08000.69%
Post-market: 11.630.00000.00%18:31 EDT
Volume:315.09K
Turnover:3.67M
Market Cap:388.48M
PE:-12.57
High:11.84
Open:11.53
Low:11.36
Close:11.55
Loading ...

retail investors who own 58% along with institutions invested in Delcath Systems, Inc. (NASDAQ:DCTH) saw increase in their holdings value last week

Simply Wall St.
·
26 Jan

Craig-Hallum Reaffirms Their Buy Rating on Delcath Systems (DCTH)

TIPRANKS
·
14 Jan

Delcath Systems Price Target Maintained With a $22.00/Share by HC Wainwright & Co.

Dow Jones
·
14 Jan

Delcath Systems Inc - Q4 Revenue Expected to Be $15.1 Mln, Full Year $37.2 Mln

THOMSON REUTERS
·
13 Jan

Press Release: Delcath Systems Announces Preliminary Fourth Quarter and Full Year 2024 Financial Results

Dow Jones
·
13 Jan

BRIEF-Delcath Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)

Reuters
·
04 Jan

Delcath Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Business Wire
·
04 Jan

Delcath Systems Announces Additional $16.3 Million in Funding From Series E and E1 Warrant Exercises

THOMSON REUTERS
·
30 Dec 2024

Delcath Systems Announces Additional $16.3 Million in Funding From Series E and E1 Warrant Exercises

Business Wire
·
30 Dec 2024

3 US Growth Companies To Watch With Up To 32% Insider Ownership

Simply Wall St.
·
30 Dec 2024

Analysts Expect Breakeven For Delcath Systems, Inc. (NASDAQ:DCTH) Before Long

Simply Wall St.
·
29 Dec 2024

Delcath Systems (DCTH) Gets a Buy from Craig-Hallum

TIPRANKS
·
05 Dec 2024

Delcath Gets FDA Clearance for Phase 2 Liver Cancer Trial

MT Newswires Live
·
02 Dec 2024

BRIEF-Delcath Systems Announces FDA Clearance of IND Application for Phase 2 Clinical Trial of HEPZATO in Liver-Dominant Metastatic Colorectal Cancer

Reuters
·
02 Dec 2024

Delcath Systems Inc - Primary Endpoint Data Expected by End of 2027

THOMSON REUTERS
·
02 Dec 2024

Delcath Systems Inc: Overall Survival, Secondary Endpoint, Is Expected in 2028

THOMSON REUTERS
·
02 Dec 2024

Delcath Systems Announces FDA Clearance of Ind Application for Phase 2 Clinical Trial of Hepzato™ in Liver-Dominant Metastatic Colorectal Cancer

THOMSON REUTERS
·
02 Dec 2024

Delcath Systems (NASDAQ:DCTH) jumps 13% this week, taking one-year gains to 330%

Simply Wall St.
·
02 Dec 2024

Delcath Systems Price Target Maintained With a $22.00/Share by HC Wainwright & Co.

Dow Jones
·
11 Nov 2024

Delcath Systems Third Quarter 2024 Earnings: Beats Expectations

Simply Wall St.
·
10 Nov 2024